| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Sorrento Therapeutics Inc (F: 8STN)
8STN Technical Analysis
5
| As on 3rd Mar 2023 8STN STOCK Price closed @ 0.30 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.24 & Strong Sell for SHORT-TERM with Stoploss of 5.68 we also expect STOCK to react on Following IMPORTANT LEVELS. |
8STNSTOCK Price
| Open | 0.25 | Change | Price | % |
| High | 0.33 | 1 Day | 0.05 | 20.00 |
| Low | 0.25 | 1 Week | -0.07 | -18.92 |
| Close | 0.30 | 1 Month | -0.79 | -72.48 |
| Volume | 4066 | 1 Year | -6.48 | -95.58 |
| 52 Week High 6.91 | 52 Week Low 0.13 | ||||
F Germany Most Active Stocks
| ENB | 47.60 | -0.92% |
| TEF | 3.84 | -0.52% |
| TEF | 3.84 | -0.52% |
| WHL | 5150.00 | -0.44% |
| WDI | 0.05 | -37.50% |
| WDI | 0.05 | -37.50% |
| WDI | 0.05 | -37.50% |
| WDI | 0.05 | -37.50% |
| WDI | 0.05 | -37.50% |
| TOE | 0.02 | 0.00% |
F Germany Top Gainers Stocks
F Germany Top Losers Stocks
| 8STN Daily Charts |
8STN Intraday Charts |
Whats New @ Bazaartrend |
8STN Free Analysis |
|
|
8STN Important Levels Intraday
| RESISTANCE | 0.45 |
| RESISTANCE | 0.40 |
| RESISTANCE | 0.37 |
| RESISTANCE | 0.34 |
| SUPPORT | 0.26 |
| SUPPORT | 0.23 |
| SUPPORT | 0.20 |
| SUPPORT | 0.15 |
8STN Forecast May 2024
| 4th UP Forecast | 2.13 |
| 3rd UP Forecast | 1.54 |
| 2nd UP Forecast | 1.18 |
| 1st UP Forecast | 0.82 |
| 1st DOWN Forecast | -0.22 |
| 2nd DOWN Forecast | -0.58 |
| 3rd DOWN Forecast | -0.94 |
| 4th DOWN Forecast | -1.53 |
8STN Weekly Forecast
| 4th UP Forecast | 3.21 |
| 3rd UP Forecast | 2.28 |
| 2nd UP Forecast | 1.70 |
| 1st UP Forecast | 1.12 |
| 1st DOWN Forecast | -0.52 |
| 2nd DOWN Forecast | -1.10 |
| 3rd DOWN Forecast | -1.68 |
| 4th DOWN Forecast | -2.61 |
8STN Forecast2024
| 4th UP Forecast | 13.37 |
| 3rd UP Forecast | 9.18 |
| 2nd UP Forecast | 6.59 |
| 1st UP Forecast | 4 |
| 1st DOWN Forecast | -3.4 |
| 2nd DOWN Forecast | -5.99 |
| 3rd DOWN Forecast | -8.58 |
| 4th DOWN Forecast | -12.77 |
Sorrento Therapeutics Inc ( F Germany Symbol : 8STN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
8STN Business Profile
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host diseases. The company also develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, it engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. Additionally, the company has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patients with melanoma; and Karolinska Institutet. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California. Address: 4955 Directors Place, San Diego, CA, United States, 92121
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service